Who owns KINNATE BIOPHARMA INC?
- Ticker: KNTE
- CUSIP Number: 49705r105
Tip: Access positions for across all investors
Analyze quarterly positions in Kinnate Biopharma with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Kinnate Biopharma stock
Who bought or sold KINNATE BIOPHARMA INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Foresite Capital Management IV | 9.7M | $26M | 0% | Mar 2024 |
|
| OrbiMed Advisors | 8.0M | $21M | 0% | Mar 2024 |
|
| Foresite Capital Management V | 3.5M | $9.4M | 0% | Mar 2024 |
|
| Lynx1 Capital Management | 2.0M | $5.3M | -1% | Mar 2024 |
|
| Viking Global Investors | 1.8M | $4.8M | 0% | Mar 2024 |
|
| Susquehanna International | 1.3M | $3.3M | 761% | Mar 2024 |
|
| Vanguard Group | 1.1M | $2.9M | 3% | Mar 2024 |
|
| Deltec Asset Management | 1.0M | $2.8M | 100% | Mar 2024 |
|
| Tang Capital Management | 978k | $2.6M | -62% | Mar 2024 |
|
| Acadian Asset Management | 965k | $2.6M | 31% | Mar 2024 |
|
| BML Capital Management | 499k | $1.3M | 7% | Mar 2024 |
|
| Yakira Capital Management | 497k | $1.3M | 100% | Mar 2024 |
|
| BlackRock | 431k | $1.1M | -42% | Mar 2024 |
|
| Group One Trading | 354k | $942k | 117940% | Mar 2024 |
|
| GSA Capital Partners | 335k | $890k | -1% | Mar 2024 |
|
| Millennium Management | 267k | $711k | -53% | Mar 2024 |
|
| Geode Capital Management | 244k | $650k | 10% | Mar 2024 |
|
| Citadel Advisors | 218k | $579k | -50% | Mar 2024 |
|
| Equitec Proprietary Markets | 202k | $536k | 100% | Mar 2024 |
|
| Marshall Wace | 156k | $415k | -20% | Mar 2024 |
|
| Trium Capital | 118k | $312k | 100% | Mar 2024 |
|
| Deutsche Bank Aktiengesellschaft | 115k | $306k | 0% | Mar 2024 |
|
| XTX Topco | 104k | $278k | 114% | Mar 2024 |
|
| Dimensional Fund Advisors | 92k | $245k | 530% | Mar 2024 |
|
| CSS | 69k | $184k | 100% | Mar 2024 |
|
| Goldman Sachs Group | 63k | $168k | -60% | Mar 2024 |
|
| Gts Securities | 60k | $160k | 100% | Mar 2024 |
|
| Skandinaviska Enskilda Banken AB | 51k | $136k | 100% | Mar 2024 |
|
| Susquehanna Portfolio Strategies | 49k | $129k | 100% | Mar 2024 |
|
| Jane Street | 42k | $113k | -45% | Mar 2024 |
|
| Leucadia National Corporation | 41k | $108k | 0% | Mar 2024 |
|
| Northern Trust | 28k | $83k | 0% | Mar 2024 |
|
| Cowen And Company | 25k | $67k | 100% | Mar 2024 |
|
| Jpmorgan Chase & Co | 25k | $66k | 39140% | Mar 2024 |
|
| Squarepoint Ops | 23k | $62k | -61% | Mar 2024 |
|
| Simplex Trading | 22k | $57k | -51% | Mar 2024 |
|
| Occudo Quantitative Strategies | 21k | $56k | -70% | Mar 2024 |
|
| SG Americas Securities | 21k | $55k | 100% | Mar 2024 |
|
| BBR Partners | 20k | $53k | 100% | Mar 2024 |
|
| Shay Capital | 19k | $52k | 100% | Mar 2024 |
|
| Florida State Board of Administration | 14k | $89k | 100% | Mar 2024 |
|
| Barclays | 14k | $38k | -3% | Mar 2024 |
|
| Point72 Asia | 14k | $38k | 541% | Mar 2024 |
|
| Mirae Asset Global Investments | 11k | $63k | 100% | Mar 2024 |
|
| Morgan Stanley | 7.4k | $20k | -68% | Mar 2024 |
|
| Qube Research & Technologies | 6.3k | $17k | 36% | Mar 2024 |
|
| Cubist Systematic Strategies | 4.1k | $11k | -67% | Mar 2024 |
|
| Rhumbline Advisers | 2.9k | $7.8k | 0% | Mar 2024 |
|
| Bank of America Corporation | 1.8k | $4.5k | -69% | Mar 2024 |
|
| Tower Research Capital | 1.1k | $2.9k | -90% | Mar 2024 |
|
| UBS Group | 818.00 | $2.2k | -84% | Mar 2024 |
|
| Federated Investors | 585.00 | $1.4k | -66% | Dec 2023 |
|
| Wells Fargo & Company | 144.00 | $382.996800 | 2% | Mar 2024 |
|
| Royal Bank of Canada | 14.00 | $0 | 367% | Mar 2024 |
|
Who sold out of Kinnate Biopharma?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Vida Ventures Advisors | Dec 2023 | 2.2M | $5.2M |
| Rock Springs Capital Management | Sep 2023 | 406k | $568k |
| Two Sigma Investments | Dec 2023 | 300k | $710k |
| Acuitas Investments | Dec 2023 | 290k | $687k |
| Two Sigma Advisers | Dec 2023 | 153k | $363k |
| D. E. Shaw & Co | Dec 2023 | 151k | $357k |
| Bridgeway Capital Management | Sep 2023 | 144k | $202k |
| Exome Asset Management | Dec 2023 | 84k | $199k |
| Connor, Clark & Lunn Investment Management | Dec 2023 | 77k | $182k |
| Verition Fund Management | Sep 2023 | 70k | $98k |
| Marquette Asset Management | Dec 2023 | 60k | $142k |
| DAFNA Capital Management | Dec 2023 | 50k | $119k |
| Springbok Capital Management | Sep 2023 | 32k | $45k |
| Two Sigma Securities | Dec 2023 | 31k | $74k |
| American Century Companies | Sep 2023 | 15k | $21k |
| Dynamic Technology Lab Private | Dec 2023 | 14k | $33k |
| Quantbot Technologies | Sep 2023 | 2.7k | $3.8k |
| Pacific Capital Wealth Advisors | Dec 2023 | 100.00 | $237.000000 |